Lyell Immunopharma, Inc.
Clinical trials sponsored by Lyell Immunopharma, Inc., explained in plain language.
-
New hope for tough colorectal cancer: LYL273 trial opens
Disease control Recruiting nowThis study tests a new drug, LYL273, in about 155 adults with metastatic colorectal cancer that has relapsed or stopped responding to standard treatments. The goal is to find a safe dose and see if it can shrink tumors. Participants must have limited liver involvement and no surg…
Phase: PHASE1, PHASE2 • Sponsor: Lyell Immunopharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New dual-targeting CAR t therapy takes on hard-to-treat lymphoma in phase 3 trial
Disease control Recruiting nowThis phase 3 trial tests a new CAR T-cell therapy called rondecabtagene autoleucel (ronde-cel) that targets two proteins (CD19 and CD20) on lymphoma cells. It is compared to standard CD19-targeting CAR T-cell therapy in 400 patients with relapsed or refractory large B-cell lympho…
Phase: PHASE3 • Sponsor: Lyell Immunopharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Double attack: new CAR t therapy targets two cancer proteins in aggressive lymphoma
Disease control Recruiting nowThis study tests a new treatment called rondecabtagene autoleucel (ronde-cel) for people with aggressive B-cell non-Hodgkin lymphoma that has come back or not responded to prior therapy. Ronde-cel is a CAR T-cell therapy that targets two proteins (CD19 and CD20) on cancer cells. …
Phase: PHASE1, PHASE2 • Sponsor: Lyell Immunopharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC